Option chain shows key data for Chocoladefabriken's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Chocoladefabriken.

Chocoladefabriken (OTC:CHLSY) Stock, Option Chain

Swiss-based Chocoladefabriken Lindt & Spruengli is a manufacturer of premium chocolate. Key brands include Lindt, Lindor, Ghirardelli, Russell Stover, Whitman's, and Caffarel. The company bought U.S.-based Russell Stover, its largest-ever acquisition, in 2014. It derives the bulk of its sales from Europe (46% of its consolidated base) but also competes in North America (41%) and the rest of the world (13%). The company operates 11 manufacturing plants in Europe and the United States. Its distribution network includes 500 own stores.

CHOCOLADEFABRIKEN U/ADR by CHOCOLADEFABRIKEN LINDT & SPRUENGLI AG

Chocoladefabriken Lindt & Spruengli AG

News

MNMD

MindMed To Be Added To The Nasdaq Biotechnology Index, Effective At Market Open On December 23, 2024

Contracts

VRAR

The Glimpse Group shares are trading higher after its subsidiary, Brightline Interactive, announced a six-figure contract with the U.S. Navy for an immersive simulator.

ACET

Adicet Bio Says First Patient Dosed In The Phase 1 Clinical Trial Evaluating ADI-270 In Patients With Metastatic/Advanced ccRCC

General

The Glimpse Group's Subsidiary Company Brightline Interactive Has Entered Into An Initial Six Figure Dollar Contract With The U.S. Navy For An Immersive Simulator, To Be Delivered In The First Half Of 2025

Jefferies analyst Michael Yee downgrades ALX Oncology Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALXO#NASDAQ">ALXO</a>) from Buy to Hold and lowers the price target from $12 to $2.

Downgrades

Price Target

Analyst Ratings

ALXO

Jefferies Downgrades ALX Oncology Holdings to Hold, Lowers Price Target to $2

Fiscal 2025 Expectations
•Organic ASV is expected to grow in the range of $90 million to $140 million during fiscal 2025.
•GAAP revenues are expected to be in the range of $2,285 million to $2,305 million.
•GAAP operating margin is expected to be in the range of 32.5% to 33.5%.
•Adjusted operating margin is expected to be in the range of 36.0% to 37.0%.
•FactSet's annual effective tax rate is expected to be in the range of 17% to 18%.
•GAAP diluted EPS is expected to be in the range of $15.10 to $15.70.
•Adjusted diluted EPS is expected to be in the range of $16.80 to $17.40.

Earnings

Guidance

FactSet Reaffirms FY25 Guidance: Sees Revenues Of $2.285B - $2.305B Vs. $2.301B Est., And Adjusted EPS Of $16.80 - $17.40 Vs. $17.17 Est.

HC Wainwright &amp; Co. analyst Sean Lee reiterates Verastem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) with a Buy and maintains $7 price target.

Reiteration

VSTM

HC Wainwright & Co. Reiterates Buy on Verastem, Maintains $7 Price Target

LASE

Laser Photonics Receives Dual Order From Oil Refiner Phillips 66 For CleanTech And MarkStar Laser Systems; No Terms Disclosed

In addition to the Fast Track designation announced today for Waldenstrom's macroglobulinemia, NX-5948 previously received Fast Track designation in January 2024 for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) after at least two lines of therapy, including a BTK inhibitor and a B-cell lymphoma 2 (BCL2) inhibitor.

NRIX

Nurix Says FDA Granted Fast Track Designation For NX-5948 For Treatment Of Adult Patients With Relapsed Or Refractory Waldenstrom's Macroglobulinemia After At Least Two Lines Of Therapy

Jefferies analyst Samad Samana upgrades Zoom Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) from Hold to Buy and raises the price target from $85 to $100.

Upgrades

Jefferies Upgrades Zoom Communications to Buy, Raises Price Target to $100

Biotech

Health Care

Management

LXEO

Lexeo Therapeutics Appoints Dr. Kyle Rasbach As Chief Financial Officer, Effective Immediately.

HC Wainwright &amp; Co. analyst Heiko Ihle reiterates Uranium Royalty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UROY#NASDAQ">UROY</a>) with a Buy and maintains $7.7 price target.

UROY

HC Wainwright & Co. Reiterates Buy on Uranium Royalty, Maintains $7.7 Price Target

REGN7508 (catalytic domain) is designed to maximize anticoagulant activity while minimizing bleeding risk, and REGN9933 (A2 domain) is designed to provide an additional option for patients with the highest bleeding risk who would otherwise not be candidates for currently available anticoagulants.&nbsp;
Per the Phase 2 results, there was an antithrombotic effect for each antibody, and no clinically relevant bleeding was observed in any treatment arm.

REGN

Regeneron Reports Phase 2 Results For Two Novel Monoclonal Antibodies Targeting Distinct Domains Of Factor XI; Says There Was Antithrombotic Effect For Each Antibody; Phase 3 Program To Be Initiated In 2025

Fiscal 2025 Financial Outlook The Company updated its full year financial outlook for fiscal 2025 which now includes Chuy's operating results, but excludes approximately $47 million, pre-tax, of expected transaction and integration related costs associated with the acquisition. The Company will provide additional details during its investor conference call scheduled for this morning at 8:30 am ET.
<ul>
<li>Total sales of approximately $12.1 billion</li>
<li>Same-restaurant sales growth of approximately 1.5%&#x2A;</li>
<li>New restaurant openings of 50 to 55</li>
<li>Total capital spending of approximately $650 million</li>
<li>Total inflation of approximately 2.5%</li>
<li>An effective tax rate of approximately 12.5%</li>
<li>Diluted net earnings per share from continuing operations of $9.40 to $9.60, excluding approximately $47 million, pre-tax, of Chuy's transaction and integration related costs&#x2A;&#x2A;</li>
<li>Approximately 118 million weighted average diluted shares outstanding</li>
</ul>

Restaurants

Darden Restaurants Expects 2025 Sales Of Approximately $12.1B Vs. Consensus Of $12.084B

Jefferies analyst Samad Samana downgrades NICE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NICE#NASDAQ">NICE</a>) from Buy to Hold and lowers the price target from $215 to $200.

NICE

Jefferies Downgrades NICE to Hold, Lowers Price Target to $200

<ul>
<li>Same-restaurant sales:</li>
</ul>
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Consolidated Darden&#x2A;</td>
<td colspan="1" rowspan="1">2.4&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Olive Garden</td>
<td colspan="1" rowspan="1">2.0&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">LongHorn Steakhouse</td>
<td colspan="1" rowspan="1">7.5&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Fine Dining&#x2A;&#x2A;</td>
<td colspan="1" rowspan="1">(5.8)&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Other Business&#x2A;</td>
<td colspan="1" rowspan="1">0.7&nbsp;%</td>
</tr>
</tbody>
</table>
</figure>

Darden Restaurants Reported Q2 2025 Same-Restaurant Sales Of 2.4%

FactSet Research Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDS#NYSE">FDS</a>) reported quarterly earnings of $4.37 per share which beat the analyst consensus estimate of $4.26 by 2.58 percent. This is a 6.07 percent increase over earnings of $4.12 per share from the same period last year. The company reported quarterly sales of $568.667 million which beat the analyst consensus estimate of $565.129 million by 0.63 percent. This is a 4.88 percent increase over sales of $542.216 million the same period last year.

Earnings Beats

FactSet Research Systems Q1 2025 Adj. EPS $4.37 Beats $4.26 Estimate, Sales $568.667M Beat $565.129M Estimate

Darden Restaurants (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) reported quarterly earnings of $2.03 per share which beat the analyst consensus estimate of $2.02 by 0.5 percent. The company reported quarterly sales of $2.89 billion which missed the analyst consensus estimate of $2.90 billion by 0.33 percent. This is a 5.97 percent increase over sales of $2.73 billion the same period last year.

Darden Restaurants Q2 2025 Adj EPS $2.03 Beats $2.02 Estimate, Sales $2.89B Miss $2.90B Estimate

TFPM

Triple Flag To Acquire Existing 0.5% GOR Royalty On Tres Quebradas Construction-stage Lithium Project From Lithium Royalty For Total Cash Consideration Of $28M

Throughout the last three months, 7 analysts have evaluated Birkenstock Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIRK#NYSE">BIRK</a>), offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $69.71, a high estimate of $83.00, and a low estimate of $60.00. A decline of 4.51% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1734609632_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A clear picture of Birkenstock Holding's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$70.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$70.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$70.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$83.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Anna Andreeva</td>
<td>Piper Sandler</td>
<td>Announces</td>
<td>Overweight</td>
<td>$65.00</td>
<td>-</td>
</tr>
<tr>
<td>Janine Stichter</td>
<td>BTIG</td>
<td>Announces</td>
<td>Buy</td>
<td>$60.00</td>
<td>-</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$70.00</td>
<td>$70.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Birkenstock Holding. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Birkenstock Holding compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Birkenstock Holding's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of Birkenstock Holding's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/BIRK/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Birkenstock Holding analyst ratings.</a>
<h2>Unveiling the Story Behind Birkenstock Holding</h2>
Birkenstock Holding PLC is a company that manufactures and sells footbed-based products, including sandals, closed-toe silhouettes, and other products, such as skincare and accessories, for everyday, leisure, and work. The company operates in four operating segments based on its regional hubs: Americas, Europe and APMA (Asia Pacific, Middle East and Africa). The company sells its products through two main channels: business-to-business (B2B) and direct-to-consumer (DTC).
<h3>Financial Milestones: Birkenstock Holding's Journey</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Birkenstock Holding's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 19.35%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Discretionary sector.
Net Margin: Birkenstock Holding's net margin is impressive, surpassing industry averages. With a net margin of 13.22%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Birkenstock Holding's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.87%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Birkenstock Holding's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 1.51%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Birkenstock Holding's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.57.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Chocoladefabriken

Chocoladefabriken (CHLSY) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga